Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Helix BioPharma ( (TSE:HBP) ) has provided an update.
Helix BioPharma Corp. has successfully closed a private placement of 4,000,000 common shares, raising CAD$3,000,000. The proceeds will be used for working capital, subject to final approval by the Toronto Stock Exchange, with a hold period of four months and one day. This financial move is expected to support the company’s ongoing operations and its strategic positioning in the immune-oncology sector.
More about Helix BioPharma
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company focused on developing unique immune-oncology therapies for cancer prevention and treatment, leveraging its proprietary DOS47 technological platform. The company is publicly traded on the TSX, OTC PINK, and Frankfurt exchanges.
YTD Price Performance: -1.74%
Average Trading Volume: 13,142
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: C$41.42M
For an in-depth examination of HBP stock, go to TipRanks’ Stock Analysis page.
